Orphan Devices Pilot Program Tackles Parliament’s Proposal Head On

The need for the EU to foster the development of orphan devices, intended for smaller patient populations with less commercial promise, is well documented. At last, action is starting.

babies
Infants Are Among Those Who Benefit From Orphan Devices For Rare Diseases • Source: Shutterstock

The European Medicines Agency has introduced a pilot program for expert panels to assist with the development and evaluation of orphan medical devices.

Challenges Of Orphan Devices Reaching Children

The guidance document, MDCG 2024-10 Clinical evaluation of orphan medical devices, points out that in many cases, orphan devices are intended for use solely or predominantly in minors and paediatric populations, and/or in emergency situations.

But, it says, generating clinical data efficiently for small patient populations is difficult, especially for vulnerable groups due to ethical and regulatory requirements, including infants and children. 

Compliance with MDR requirements, including certification, it says, can lead to increased and unpredictable financial costs, hindering manufacturers from placing orphan devices on the EU market due to low sales not covering expenses.

This program provides free advice to selected manufacturers and notified bodies on orphan device status and the data needed for...

Welcome to Medtech Insight

Create an account to read this article

More from Europe

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.

Bates To Energize UK Office For Life Sciences

 
• By 

Steve Bates, head of the UK BioIndustry Association, has been appointed executive chair of the government’s Office for Life Sciences as the UK restructures its life sciences approach and drives health outcomes with a new NHS Long-Term Care plan.

International Reliance Gets UK MHRA OK In Drive For Agile Pre-Market Regulation – CE Marking Next

 
• By 

The UK government’s response to MHRA public consultation on risk proportionate device routes to market and physical UKCA markings adds momentum to drive for modern, agile system. Another consultation in late 2025 will propose indefinite recognition of CE-marked devices in Great Britain.

Expert Panels Remain Tough On Manufacturers And Their Notified Bodies

 

The EU’s extra layer of checks on clinical evidence is proving a difficult, and sometimes humiliating process, for many device companies whose products have come under the spotlight.

More from Geography

Medtech M&A Resurges: How To Define Startup Exit Strategy

 

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.

HHS Suggests Drastic Reductions To Skin Substitute Payments

 
• By 

The US Department of Health and Human Services has proposed cutting Medicare reimbursement for skin substitutes used in chronic wound care by up to 90%. The change aims to address rising costs but could harm patient access and treatment quality, prompting concerns from industry stakeholders.

Injuries And Deaths Linked To Baxter Infusion Pump

 

The US FDA says Baxter has notified customers about an issue with its Novum IQ Syringe Pump that is linked to two deaths and multiple injuries.